A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

ConclusionsContinuous veliparib is safe and tolerable. The RP2D was 400  mg BID. There is evidence of clinical activity of veliparib in patients withBRCAmut andBRCAwt cancers.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research